neurotensin

Neurotensin (1-6) affects dopamine release from striatum.

Neurotensin is a 13 amino acid neuropeptide that is implicated in the regulation of luteinizing hormone and prolactin release and has significant interaction with the dopaminergic system.

Neurotensin TFA (39379-15-2 free base) is an endogenous 13 amino acid neuropeptide with profound opioid-independent analgesic effects. It behaves as a neurotransmitter in the brain, as a hormone in the gut, and also as a neuromodulator. It is implicated in the pathophysiology of several CNS disorders (including schizophrenia, Parkinson's disease, drug abuse, pain, cancer, inflammation, eating disorders, and central control of blood pressure) due to its association with a wide variety of neurotransmitter systems such as dopaminergic, sertonergic, glutamatergic, GABAergic, and cholinergic systems. It has a role as a human metabolite, a mitogen, a neurotransmitter and a vulnerary.

[Lys8, Lys9]-Neurotensin (8-13) (JMV438) is a Neurotensin analog that elicits analgesic effects by activating the G protein-coupled receptors NTS1 and NTS2, with K i values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively.

[Lys8, Lys9]-Neurotensin (8-13) acetate, a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2, with Ki values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively[1].

[D-Trp11]-Neurotensin is a compound that functions as a selective antagonist of Neurotensin (NT) in perfused rat hearts, while exhibiting full agonist properties in guinea pig atria and rat stomach strips. Additionally, this compound can inhibit hypotension induced by NT.

Neurotensin(8-13) 3TFA is Neurotensin (NT) fragment. Neurotensin(8-13) 3TFA results in a decrease in cell-surface NT1 receptors (NTR1) density.

Neurotensin-related hexapeptide exists in retinal ganglion cells and in their central projections in pigeons and may be utilized as a neuroactive substance by the central terminals of numerous retinal ganglion cells in birds.

Neurotensin(8-13) is Neurotensin (NT) fragment, Neurotensin(8-13) results in a decrease in cell-surface NT1 receptors (NTR1) density.

SR 142948 is a neurotensin (NT) receptor antagonist.

KYP-2047 is a very potent, selective Prolyl oligopeptidase (POP) inhibitor.

Meclinertant (SR 48692) is a neurotensin receptor-1 (NT1) antagonist that blocks neurotensin-induced excitation and can be used to study neurological disorders.

LM11A-31 dihydrochloride is a water-soluble, non-peptide with high blood-brain barrier permeability.LM11A-31 dihydrochloride, a p75NTR (neurotrophin receptor p75) Ligand, is a potent proNGF (nerve growth factor) antagonist.

SB-657510 is a urotensin II (UII) receptor (UT) antagonist. The Ki values of UT for human, monkey, cat, rat and mouse were 61, 17, 30, 65 and 56 nM, respectively. SB-657510 plays an anti-inflammatory role by inhibiting UII-induced inflammatory mediators, such as adhesion molecules, in human vascular endothelial cells and upregulation of cytokines and tissue factors. SB 657510 has a therapeutic effect on diabetes-related atherosclerotic disease in diabetic mouse models.

SBI-553 is an effective and brain penetrant NTR1 allosteric modulator (EC50: 0.34 μM).

(±)-AC 7954 hydrochloride is a urotensin-II (UT) receptor activator.

SB 611812 is an antagonist of urotensin-II (UT) and can be used in studies about the treatment of cardiovascular disease.

Latozinemab (AL001) is a potent and selective recombinant humanized monoclonal antibody against Sortilin.Latozinemab has a high affinity for Sortilin and interrupts the interaction between the granule protein precursor (PGRN) and the Sortilin receptor.Latozinemab can be used to study of dementia and Alzheimer's disease.

Compound 10, an hNTS1R agonist-1, acts as a full agonist with a strong affinity for hNTS1R (K i: 6.9 nM), showing the ability to cross the blood-brain barrier (BBB). It not only enhances motor function but also improves memory in a mouse model of Parkinson's disease (PD). Additionally, this compound is an analog of Neurotensin(8-13) and demonstrates neuroprotective properties [1].

BVFP is a PGRN-SORT1 inhibitor/SORT1 antagonist that binds to key residues 588-593 of PGRN, a multifunctional secreted glycoprotein, and SORT1, a neuronal receptor for PGRN.BVFP is able to block PGRN-SORT1 binding, restore extracellular levels of PGRN , inhibits SORT1-mediated rPGRN endocytosis, and has therapeutic potential for frontotemporal lobe dementia (FTLD-TDP).

SORT-PGRN Interaction Inhibitor 3 (Compound 13), with an IC50 value of 0.17 μM, acts as an inhibitor of the SORT-PGRN interaction, and is utilized in the study of neurodegenerative diseases [1].

SORT-PGRN interaction inhibitor 1 is a potent inhibitor of the sortilin-progranulin interaction, with an IC50 of 2 μM.

Kinetensin acetate(103131-69-7 free base) is isolated from pepsin-treated human plasma. Kinetensin acetate(103131-69-7 free base) is a neurotensin-like peptide.

Substance P 1-9 aceate is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.